Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
A live webcast of the fireside chat will be available on the Investors section of Contineum’s website and a replay will be available following the conclusion of the event.
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Contineum is focused on targeting biological pathways associated with specific clinical impairments, that Contineum believes, once modulated, may demonstrably impact the course of disease. Contineum has a pipeline of internally-developed programs to address multiple NI&I disorders. PIPE-791 is an LPA1 receptor antagonist which recently completed a Phase 1 healthy volunteer clinical trial to support ongoing clinical development for IPF and progressive multiple sclerosis. PIPE-307, a selective inhibitor of the M1 receptor, is currently in a Phase 2 clinical trial for relapse-remitting multiple sclerosis, and a Phase 2 trial in depression is planned to initiate in 2024. Contineum is developing PIPE-307 in collaboration with Johnson & Johnson Innovative Medicines.
Contineum is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604132442/en/
CFO
pslover@contineum-tx.com
Source: